$23.37
-0.04-0.17%
At Close: -
15 minutes delayed
Comments
Loading...
Latest news for Harbor ETF Trust Harbor Multi-Asset Explorer ETF (ARCA:MAPP)
Harbor ETF Trust Harbor Multi-Asset Explorer ETF (ARCA: MAPP)
Categories: All
Friday, March 01, 2013
Friday, February 15, 2013
Thursday, February 07, 2013
Friday, February 01, 2013
Wednesday, January 30, 2013
Monday, January 28, 2013
Thursday, January 24, 2013
Wednesday, January 23, 2013
- Benzinga's M&A Chatter for Wednesday January 23, 2013
- Leerink Swann Downgrades MAP Pharmaceuticals, Inc. to Market Perform
- Mid-Day Market Update: AMD Remains Up, Cyberonics Takes a Beating
- MAP Skyrockets Off the Map on Allergan Acquisition
- Mid-Morning Market Update: Cree Continues Earnings Fueled Rally, General Dynamics Feels Defense Spending Slowdown
- Allergan to Acquire MAP Pharmaceuticals for $25.00/Share
Friday, November 23, 2012
Wednesday, August 01, 2012
Tuesday, July 31, 2012
Friday, July 13, 2012
Thursday, July 12, 2012
Monday, June 25, 2012
Monday, May 07, 2012
Friday, May 04, 2012
Thursday, April 12, 2012
Friday, March 30, 2012
Thursday, March 29, 2012
Wednesday, March 28, 2012
Tuesday, March 27, 2012
- Wedbush Securities Maintains MAP Pharmaceutic...
- MAP Pharmaceuticals Trading 0.8% Lower on Hea...
- Morning Social Media Outlook for Tuesday March 27 (ISTA, LNDC, CALM, MAPP)
- MAP Pharmaceuticals Trading 10.7% Lower on He...
- UPDATE: Map Says It Will Provide Updates on F...
- UPDATE: MAP Says FDA Didn't Mention Concerns ...
- UPDATE: MAP Pharma Will Request FDA Meeting T...
- MAP CEO Says Approval Milestone with Allergan...
- MAP Pharma Falls as Much as 35% on CRL
- UPDATE: MAP CEO Says FDA Wanted More Time to ...
- UPDATE: MAP CEO Says FDA Had Questions on Inh...
- MAP CEO Says Third-Party Manufacturer was FDA...
- Benzinga's Top Pre-Market Losers
- MAP Pharma Says FDA Didn't Require More Clini...
- JP Morgan on MAP Pharmaceuticals Delayed Approval of Levadex